Get the Stockscreener App
3.37
1.75%
-0.06
After Hours:
3.37
Niagen Bioscience Inc stock is traded at $3.37, with a volume of 488.55K.
It is down -1.75% in the last 24 hours and down -7.67% over the past month.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
See More
Previous Close:
$3.43
Open:
$3.42
24h Volume:
488.55K
Relative Volume:
0.53
Market Cap:
$268.40M
Revenue:
$130.42M
Net Income/Loss:
$18.64M
P/E Ratio:
15.44
EPS:
0.2182
Net Cash Flow:
$4.05M
1W Performance:
-2.88%
1M Performance:
-7.67%
6M Performance:
-46.42%
1Y Performance:
-75.72%
1-Day Range:
$3.355
$3.515
1-Week Range:
$3.355
$3.575
52-Week Range:
$3.35
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Name
Niagen Bioscience Inc
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
3.37 | 280.35M | 130.42M | 18.64M | 4.05M | 0.2182 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Canaccord Genuity | Buy |
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Niagen Bioscience Inc Stock (NAGE) Latest News
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition - Investing.com
Earnings call transcript: Niagen Bioscience Q1 2026 sees growth in e-commerce - Investing.com
Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program - Yahoo Finance
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science - Business Wire
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference - Stock Titan
Is Niagen Bioscience’s (NAGE) NAD+ Research Push Quietly Redefining Its Competitive Moat? - simplywall.st
Niagen Bioscience (NAGE) Rebrands Research Program - GuruFocus
Niagen Bioscience renames research program By Investing.com - Investing.com Nigeria
Niagen Bioscience renames research program - Investing.com
Q4 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Q1 2026 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Q2 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
Q3 2025 Niagen Bioscience Inc Earnings Call Transcript - GuruFocus
NAGE Stock Price, Quote & Chart | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $10 - Moomoo
NAGE Technical Analysis | Trend, Signals & Chart Patterns | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement Claims - The Manila Times
National Advertising Review Board Recommends Niagen Modify - GlobeNewswire
NAGE News | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
Niagen Bioscience Earnings Call Highlights Growth Push - TipRanks
How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower - Yahoo Finance
Is Niagen Bioscience’s (NAGE) Telehealth Niagen Plus Launch a Turning Point in Its Direct-Access Strategy? - simplywall.st
Niagen Bioscience stock price target lowered to $11 by H.C. Wainwright - Investing.com Australia
HC Wainwright Lowers Niagen Bioscience (NASDAQ:NAGE) Price Target to $11.00 - MarketBeat
Assessing Niagen Bioscience (NAGE) Valuation After Earnings Strength And New NAD Plus Delivery Initiatives - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results - Post Register
Will Niagen Bioscience’s (NAGE) Telehealth NAD+ Push Redefine Its Core Therapeutic Focus? - Yahoo Finance
Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results - Streetwise Reports
Niagen Bioscience Announces Participation in Upcoming Investor Conferences - PharmiWeb.com
Niagen Bioscience Announces Participation in Upcoming May 2026 Investor Conferences - BioSpace
Niagen Bioscience Q1 2026 slides: e-commerce surges 14% amid transition By Investing.com - Investing.com South Africa
Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED) - Benzinga
Niagen Bioscience reaffirms 10%-15% 2026 growth outlook while increasing marketing spend expectations - MSN
Niagen Bioscience Inc Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Niagen Bioscience Q1 2026 sees growth in e-commerce By Investing.com - Investing.com South Africa
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Niagen (NAGE) Q1 2026 Earnings Call Transcript - AOL.com
Niagen Bioscience Inc Stock (NAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Niagen Bioscience Inc Stock (NAGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.81 |
4,465 |
30,406 |
7,372 |
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.85 |
2,220 |
15,210 |
2,220 |
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):